Cargando…
Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors
SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) are now incorporated into the management of GI tumors. The heterogenous nature of these tumors, however, reveals a lack of ICI consistency in effectiveness. Certain biomarkers have emerged as being potentially predictive for ICI effectiveness. Our...
Autores principales: | Rogers, Jane E., Yamashita, Kohei, Sewastjanow Silva, Matheus, Ajani, Jaffer A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563283/ https://www.ncbi.nlm.nih.gov/pubmed/36230726 http://dx.doi.org/10.3390/cancers14194804 |
Ejemplares similares
-
Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target
por: Rogers, Jane E., et al.
Publicado: (2023) -
Challenges and Prospects of Patient-Derived Xenografts for Cancer Research
por: Jin, Jiankang, et al.
Publicado: (2023) -
Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
por: Charalampakis, Nikolaos, et al.
Publicado: (2022) -
Programmed death ligand‐1 expression in gastrointestinal cancer: Clinical significance and future challenges
por: Yamashita, Kohei, et al.
Publicado: (2020) -
Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers
por: Kim, Bum Jun, et al.
Publicado: (2017)